Cobblestone Capital Advisors LLC NY Acquires 467 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Cobblestone Capital Advisors LLC NY lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,807 shares of the medical equipment provider’s stock after acquiring an additional 467 shares during the period. Cobblestone Capital Advisors LLC NY’s holdings in Zimmer Biomet were worth $347,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Zimmer Biomet by 0.7% in the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after acquiring an additional 166,763 shares during the last quarter. Dodge & Cox lifted its stake in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after purchasing an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after buying an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Zimmer Biomet by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after buying an additional 58,060 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $103.21 on Tuesday. The company has a fifty day moving average of $101.87 and a 200-day moving average of $97.64. The firm has a market capitalization of $20.45 billion, a P/E ratio of 25.11, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research reports. Royal Bank Of Canada set a $111.00 price objective on shares of Zimmer Biomet in a report on Friday, October 10th. Evercore ISI lowered their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Stifel Nicolaus raised their target price on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 target price for the company. Finally, Canaccord Genuity Group restated a “hold” rating and set a $101.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $111.94.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.